News

On October 18, the Global MicroLabTalk Forum 2025, jointly hosted by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) and Autobio, was grandly convened. Over 100 industry experts and scholars from 27 countries gathered to engage in in-depth discussions and exchanges on cutting-edge topics including new technologies, methodologies, and clinical applications in microbiological testing.

Yang Zengli, General Manager of Autobio, delivered an opening address. He emphasized that the global in vitro diagnostics industry is experiencing rapid development, with technological innovation reshaping the landscape of laboratory medicine at an unprecedented pace. Microbial testing, serving as a critical link connecting pathogen diagnosis, health management, and treatment decisions, is gaining increasing prominence. Autobio possesses deep expertise in microbiological testing, with strong capabilities in culture, identification, and antimicrobial susceptibility testing. The company's "Microbiological Laboratory Management System" enables seamless integration of data across all microbiological testing processes, providing comprehensive solutions for clinical microbiological testing. He emphasized that amid profound industry transformation, only by actively embracing technological innovation, accelerating intelligent transformation, and continuously optimizing quality management systems can companies seize development opportunities and lead the future direction of microbiological testing.

During the keynote presentations, over a dozen leading global experts in microbiological testing delivered an academic feast of both depth and breadth. Focusing on critical aspects like culture, identification, antimicrobial susceptibility testing, and data integration, they systematically analyzed current bottlenecks and breakthrough pathways in microbiological testing technologies, sharing clinical application experiences and cutting-edge research findings. Experts from Germany, the UK, Serbia, Egypt, and other countries focused on mass spectrometry platforms, sharing practical applications across clinical diagnostics and food safety while offering forward-looking perspectives on future technological directions. Experts from Belgium, Brazil, and other countries centered their discussions on antimicrobial susceptibility testing platforms, detailing the latest developments in bacterial resistance monitoring across nations and emphasizing the critical role of susceptibility test results in guiding precise clinical drug administration. Meanwhile, specialists from Saudi Arabia, Egypt, Belgium, and others explored blood culture platforms, sharing clinical evaluation outcomes and typical application cases tailored to diverse regional and patient group testing needs.

Chen Fei, Director of Autobio's International Trade and Cooperation Center, addressed challenges and innovation directions in the diagnostics industry while highlighting Autobio's international expansion achievements. He stated that Autobio is accelerating its global footprint, with products now successfully reaching over 100 countries and regions worldwide. Moving forward, Autobio will continue delivering superior products and services to meet diverse global customer needs, injecting fresh momentum into the advancement of global laboratory medicine.

Fu Guangyu, Executive Vice President of Autobio, delivered the concluding remarks. He emphasized that as a steadfast pioneer in China's microbial diagnostics field, Autobio remains committed to its core mission of "serving human health" by tackling critical technological challenges in microbial testing. Concurrently, Autobio will continue building open, collaborative international platforms to maintain close partnerships with global leading institutions, experts, and clinical users. Together, they will advance the intelligent development of microbial testing technologies, ensuring cutting-edge innovations reach frontline clinical settings to benefit patients worldwide.

During the conference, Autobio's comprehensive microbiology solutions exhibition area drew significant attention from attendees. The display featured flagship products including the next-generation microbiology mass spectrometry system Autof T Series and the BC120 Plus microbial incubator. Staff provided live demonstrations, detailed technical parameter explanations, and patiently addressed inquiries to fully showcase each instrument's capabilities while promptly responding to specific needs.

Following the conference, attending experts visited China's first Museum of Laboratory Medicine, embarking on a field exploration journey "from theory to practice." The museum's extensive exhibits, vivid scene recreations, and advanced digital displays systematically traced the evolution of laboratory medicine globally—from early manual testing methods to today's intelligent systems, and from single-pathogen detection to comprehensive lifecycle health management. This journey showcased the arduous explorations and remarkable achievements throughout the field's development. Experts also toured Autobio's intelligent production workshop, gaining firsthand insight into the deep integration of automation and precision management in manufacturing processes. They highly commended the industrial ecosystem layout and technology transfer capabilities of Autobio's in vitro diagnostics industrial park.

Founded in 1952, the IFCC is a globally authoritative organization in clinical chemistry and laboratory medicine. With members from 119 countries and regions and over 50,000 expert members, it plays a pivotal role in global medical laboratory standardization, quality system development, and cross-regional technical collaboration.

This intensive, full-day academic exchange between Autobio and IFCC not only efficiently disseminated cutting-edge technological achievements in global microbiological testing but also significantly advanced the convergence of concepts and mutual learning of experiences among different nations in this field. Moving forward, Autobio will continue to prioritize innovation as its core driver, guided by market demand, to continuously enhance product and service quality. Collaborating with global partners, Autobio is committed to advancing progress in the field of microbiological testing and diagnostics, making greater contributions to safeguarding human health.